Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.

ID: ALA4316614

Journal: Bioorg Med Chem Lett

Title: Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.

Authors: Liu Y, Liang Y, Jiang J, Qin Q, Wang L, Liu X.

Abstract: The novel hydroxyanthraquinone derivatives containing nitrogen-mustard and thiophene group were designed to covalently bind to topoisomerase II, and their structures were confirmed by nuclear magnetic resonance and high resolution mass spectrometer technologies in this article. The in vitro cytotoxicity against different cancer cell lines and one normal liver cell line (L02) was evaluated by MTT assay. Compound A1 was the most potent anti-proliferative agent against the human liver cancer HepG-2 cells (IC₅₀ = 12.5 μM), and there is no obvious growth inhibitory effect on normal liver tissue L02 cells. The good cytotoxicity and selectivity of compound A1 suggest that it could be a promising lead for further optimization. The mechanisms of action about compound A1 and A4 were further investigated through analysis of cell apoptosis. Confocal microscopy tracks the location of compound A1 in the cell, which could enter the cytoplasm and nucleus, and induce severe deformation of the nucleus. The docking study demonstrated that A1 could interact with the catalytic active site in topoisomerase II.

CiteXplore: 30846253

DOI: 10.1016/j.bmcl.2019.02.026

Patent ID: ┄